Chemistry: analytical and immunological testing – Lipids – triglycerides – cholesterol – or lipoproteins
Reexamination Certificate
2006-08-29
2006-08-29
Duffy, Patricia A. (Department: 1645)
Chemistry: analytical and immunological testing
Lipids, triglycerides, cholesterol, or lipoproteins
C435S007100, C530S388250, C530S389300
Reexamination Certificate
active
07098036
ABSTRACT:
Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as “dipsticks”. The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample. The amount of lipid associated with a bound lipoprotein or the amount of apolipoprotein bound on the dipstick is quantitated using an appropriate method, for example, by staining with a lipid stain or reaction with a second labelled antibody. The intensity of the stain on the dipstick is proportional to the concentration of the lipoprotein lipid or apolipoprotein circulating in the blood and can be quantitated by comparison with standards containing known amounts of lipid.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4677057 (1987-06-01), Curtiss et al.
patent: 4786589 (1988-11-01), Rounds
patent: 5126276 (1992-06-01), Fish et al.
patent: 0257778 (1988-02-01), None
patent: 0 257 778 (1988-03-01), None
patent: 0262854 (1988-04-01), None
patent: 0 407 035 (1991-01-01), None
patent: 0407035 (1991-09-01), None
patent: WO 86/05493 (1986-09-01), None
patent: WO 93/07165 (1993-04-01), None
patent: WO 93/18067 (1993-09-01), None
Froster et al, Biochem. Soc. Trans. 18(6) : 1180, Dec. 1990.
Mills et al eds, in Laboratory Techniques in biochemistry and molecular biology, vol. 14, A Guidedbook to Lipoprotein technique, EISEVLER 1984, PP. 472-478.
Zhow et al. Hubei Yixueyuan Xuebao vol. 11, No. 4, pp. 298-302, 1990.
Vance et al in Biochemistry of Lipids and Membrane , p. 426 & 427, 1985.
Alaupovic, P., et al., “Characterization of Potentially Atherogenic Triglyceride-rich Lipoprotein Particles”,Klin Wochenschr, 68:38-42 (1990).
Alaupovic, P., et al., “Distribution of Lipoprotein Families in Major Density Classes of Normal Human Plasma Lipoproteins”,Biochim. Biophys. Acta, 260:689-707 (1972).
Alaupovic, P., et al., “Isolation and Characterization of an apoA-II-Containing Lipoprotein (LP-A-II:B Complex) from Plasma Very Low Density Lipoproteins of Patients with Tangier Disease and Type V Hyperlipoproteinemia”,J. Lipid Res., 32:9-19 (1991).
Alaupovic, P., “David Rubinstein Memorial Lecture: The Biochemical and Clinical Significance of the Interrelationship Between Very Low Density and High Density Lipoproteins”,Can. J. Biochem., 59:565-579 (1981).
Arntzenius, A.C., “Regression of Atherosclerosis—Benefit can be Expected from Low LDL-C and High HDL-C Levels”,Acta. Cardiol., 46:431-438 (1991).
Assmann, G., et al., “The Hypertriglyceridemias: Risk and Management”,Am. J. Cardiol., 68(3):1A-4A (1991).
Atmeh, R.F., et al., “Subpopulations of Apolipoprotein A-I in Human High-Density Lipoproteins, Their Metabolic Properties and Response to Drug Therapy”,Biochim. Biophys. Acta, 751:175-188 (1983).
Avogardo, P., et al., “Are Apolipoproteins Better Discriminators than Lipids for Atherosclerosis?”,Lancet, 1:901-903 (1979).
Barth, J.D., et al., “Progression and Regression of Atherosclerosis, What Roles for LDL-Cholesterol and HDL-Cholesterol: A Perspective”,Eur. Heart J., 12:952-957 (1991).
Blankenhorn, D.H., et al., “Prediction of Angiographic Change in Native Human Coronary Arteries and Aortocoronary Bypass Grafts”,Circulation, 81(2):479-476 (1990).
Cardin, A.D., et al., “Degradation of Apolipoprotein B-100 of Human Plasma Low Density Lipoproteins by Tissue and Plasma Kallikreins”,J. Biol. Chem., 259(13):8522-8528 (1984).
Clackson, T. et al.,Nature, 352: 624-628 (1991).
Curry, M.D., et al., “Determination of Apolipoprotein A and Its Constitutive A-I and A-II Polypeptides by Separate Electroimmunoassays”,Clin. Chem., 22(3):315-322 (1976).
Curry, M.D., et al., “Electroimmunoassay, Radioimmunoassay, and Radial Immunodiffusion Assay Evaluated for Quantification of Human Apolipoprotein B”,Clin. Chem., 24(2):280-286 (1978).
Curry, M.D., et al., “Determination of Human Apolipoprotein E by Electroimmunoassay”,Biochim. Biophys. Acta, 439:413-425 (1976).
Curry, M.D., et al., “Quantitative Determination of Human Apolipoprotein C-III by Electroimmunoassay”,Biochim. Biophys. Acta, 617:503-513 (1980).
Cwirla, S.E. et al.,Proc. Natl. Acad. Sci. USA, 87: 6378-6382 (1990).
Friedewald, W.T., et al., “Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge”,Clin. Chem., 18(6):499-502 (1972).
Fruchart, J.E., et al., “Apolipoprotein A-Containing Lipoprotein Particles: Physiological Role, Quantification, and Clinical Significance”,Clin. Chem., 38(6):793-797 (1992).
Fruchart et al., Clin. Chem., 28(1):59-62, (1982).
Galeano, N.F., et al.,J. Biol. Chem., “Apoprotein B Structure and Receptor Recognition of Triglyceride-rich Low Density Lipoprotein (LDL) is Modified in Small LDL but Not in Triglyceride-rich LDL of Normal Size”, 269(1):511-519 (1994).
Galeano, N.F. et al.,J. Biol. Chem., 269:511-519 (1994).
Galfré, G., et al., “Preparation of Monoclonal Antibodies: Strategies and Procedures”,Methods Enzymol., 73:3-46 (1981).
Glenner, G.G., “Formazans and Tetrazolium Salts”,In: H.J. Conn's Biological Stains, The Williams and Wilkins Company, USA, 225-235 (1990).
Goding, “monoclonal Antibodies: Principles and Practice”, Academic Press, Inc, New Yorkpp. 56-97 (1983).
Gohlke, H., “Influence of the LDS-/HDL-Cholesterol Ratio on Progression and Regression of Atherosclerotic Lesions. A Review of Controlled Angiographic Intervention Trials”,Wien Klin. Wochenschr., 104(11):309-313 (1992).
Gordon, T., et al., “High Density Lipoprotein as a Protective Factor Against Coronary Heart Disease”,Am. J. Med., 62:707-714 (1977).
Harduin, P., et al., “Modulation of the Expression of Human LDL-Apo B-100 Epitopes by Lipids and Apolipoproteins”,Arterioscl. Thromb., 13(4):529-535 (1993).
Hollinger, P., et al., “‘Diabodies’: Small bivalent and Bispecific Antibody Fragments”,Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
Hoogenboom, H.R., et al., “Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains”,Nucl. Acids Res., 19(15):4133-4137 (1991).
Ito, W., et al., “Development of an Artificial Antibody System with Multiple Valency Using an Fv Fragment Fused to a Fragment of Protein A”,J. Biol. Chem., 268(27):20668-20675 (1993).
Kane, J.P., “Characterization of Apolipoprotein B-Containing Lipoproteins”,Method. Enzymol., 129:123-129 (1986).
Kashyap, M.L., et al., “Radioimmunoassay of Human Apolipoprotein CII—A Study in Normal and Hypertriglyceridemic Subjects”,J. Clin. Invest., 60:171-180 (1977).
Keidar, S., et al., “A High Carbohydrate-Fat Free Diet Alters the Proportion of Heparin-Bound VLDL in Plasma and the Expression of VLDL-ApoB-100 Epitopes”,Metabolism, 39(3):281-288 (1990).
Koren, E., et al., “Isolation and Characterization of Simple and Complex Lipoproteins Containing Apolipoprotein F from Human Plasma”,Biochemistry, 21:5347-5351 (1982).
Koren, E., et al., “Apolipoprotein A-I and Apolipoprotein B Containing Lipoprotein Particles in Coro
Koren Eugen
Koscec Mirna
Duffy Patricia A.
Fulbright & Jaworski
Okalahoma Medical Research Foundation
LandOfFree
Antibodies to lipoproteins and apolipoproteins and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to lipoproteins and apolipoproteins and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to lipoproteins and apolipoproteins and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3692530